

**BRAWN BIOTECH LTD.**

To,

**BSE Limited,  
25<sup>th</sup> Floor, P. J. Towers,  
Dalal Street Fort,  
Mumbai- 400001**

**BSE Scrip Code: 530207**

**Scrip ID: BRAWN**

**Subject:** Integrated Filing (Financials) for the quarter and nine months ended December 31, 2024


Dear Sir/Madam,

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we are submitting herewith the Integrated Filing (Financials) for the quarter and nine months ended December 31, 2024.

This is for your information and records.

This will also be hosted on the Company's website.

**Yours Sincerely,  
Brawn Biotech Limited**



**Priyanka Sharma  
Company Secretary & Compliance Officer  
Membership No.: A50385  
Encl: As above**



**BRAWN BIOTECH LTD.**

**CIN NO.: L74899DL1985PLC022468**

**Works :** Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA  
Email: [distribution@brawnbiotech.com](mailto:distribution@brawnbiotech.com) | Website: [www.brawngroup.in](http://www.brawngroup.in)

**Regd. Office :** C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com)

*...for better life*



C06C5

**BRAWN BIOTECH LTD.**


**BRAWN BIOTECH LIMITED**  
CIN:L74899DL1985PLC022468  
REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024  
**STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31st DECEMBER 2024**

Sr.	Particulars	Quarter ended			Nine Months ended		Rs in Lacs
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	Year Ended
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Revenue from operations						
a	Revenue from operations						
b	Other Income	384.48	329.68	284.28	1,120.57	1,304.82	1,649.47
	Total Revenue	0.08	0.13	0.38	0.21	0.42	8.81
2	Expenses	384.56	329.81	284.66	1,120.79	1,305.23	1,658.28
a	Cost of material consumed						
b	Purchase of stock-in-trade						
c	Change in inventories of finished goods, work in progress and stock in trade	800.26	245.20	283.82	1,320.05	1,069.65	1,558.90
d	Employee Benefit expenses	-454.49	31.69	-27.53	-321.20	78.18	-122.53
e	Depreciation and amortisation expenses	20.93	28.16	35.77	90.14	107.90	140.01
f	Finance Cost	3.08	2.71	2.71	8.33	7.17	9.94
g	Other expenses	0.01	0.15	0.01	0.16	0.16	0.38
	Total Expenses	57.95	56.27	50.62	154.67	162.42	225.99
		427.75	364.18	345.40	1,251.15	1,425.48	1,812.70
3	Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)						
4	Other Income	-43.18	-34.37	-60.74	-130.37	-120.24	-154.42
5	Profit from ordinary activities before exceptional items (3-4)						
6	Exceptional Items	-43.18	-34.37	-60.74	-130.37	-120.24	-154.42
7	Profit from ordinary activities before tax (5-6)						
8	Tax Expenses	-43.18	-34.37	-60.74	-130.37	-120.24	-154.42
9	Profit (Loss) for the period from continuing operations (7-8)						
10	Profit/(loss) from discontinuing operations	-43.18	-34.37	-60.74	-130.37	-120.24	-154.42
11	Tax expense of discontinuing operations						
12	Profit/(loss) from discontinuing operations (after tax) (10-11)						
13	Profit (Loss) for the period (9+12)						
14	Other Comprehensive Income	-43.18	-34.37	-60.74	-130.37	-120.24	-154.42
	Total Comprehensive Income	0.06	5.71	0.17	3.80	-0.42	0.28
15	Details of equity share capital	-43.12	-28.66	-60.57	-126.56	-120.66	-154.14
	Paid-up equity share capital	300.03	300.03	300.03	300.03	300.03	300.03
	Face value of equity share capital						
16	Reserve excluding Revaluation Reserve						
17	Earnings per share						
i	Basic earnings per share						
ii	Diluted earnings per share	-1.44	-0.96	-2.02	-4.22	-4.02	-5.14
		-1.44	-0.96	-2.02	-4.22	-4.02	-5.14

NOTES :-

- Results for the quarter ended on 31st December, 2024 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 12th February, 2025.
- The Statutory Auditors carried out the limited review for quarter ended 31st December, 2024. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.  
The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone Un-audited Financial Results for the quarter ended on 31-12-2024 are available on company's website [www.brawnbiotech.com](http://www.brawnbiotech.com) and BSE website [www.bseindia.com](http://www.bseindia.com).
- Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board  
For Brawn Biotech Limited

  
Bej Raj Gupta  
Director  
DIN NO. 00924969  
Date: 12.02.2025  
Place: Delhi

**BRAWN BIOTECH LTD.****CIN NO.: L74899DL1985PLC022468**

**Works :** Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA  
Email: [distribution@brawnbiotech.com](mailto:distribution@brawnbiotech.com) | Website : [www.brawngroup.in](http://www.brawngroup.in)

**Regd. Office :** C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com)

...for better life





**RAJIV UDAI & ASSOCIATES**  
CHARTERED ACCOUNTANTS

To,  
The Board of Directors of  
Brawn Biotech Limited


We have reviewed the accompanying statement of unaudited financial results of **Brawn Biotech Limited** for the period ended 31<sup>st</sup> December 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For Rajiv Udai & Associates  
Chartered Accountants  
Firm Registration No. 018764N

  
Rajeev Jain  
Partner  
Membership No. 099767  
UDIN: 25099767BMIVB1951



Place: Delhi  
Date: 12-02-2025



**BRAWN BIOTECH LTD.**

**B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.**

Not Applicable

**C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES:**

S.No.	Particulars	In INR Crore
<b>1</b>	<b>Loans / revolving facilities like cash credit from banks / financial institutions</b>	
A.	Total amount outstanding as on date	0
B.	Of the total amount outstanding, amount of default as on date	0
<b>2</b>	<b>Unlisted debt securities i.e. NCDs and NCRPS</b>	
A.	Total amount outstanding as on date	0
B.	Of the total amount outstanding, amount of default as on date	0
<b>3.</b>	<b>Total financial indebtedness of the listed entity including short term and long-term debt</b>	<b>0</b>

**D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half yearly filings i.e., 2nd and 4th quarter) :**

Not Applicable

**E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4<sup>th</sup> quarter)**

Not Applicable



**BRAWN BIOTECH LTD.**

**CIN NO.: L74899DL1985PLC022468**

**Works :** Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA  
Email: [distribution@brawnlabs.in](mailto:distribution@brawnlabs.in) | Website : [www.brawngroup.in](http://www.brawngroup.in)  
**Regd. Office :** C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com)

*...for better life*